Crispr Therapeutics AG (NASDAQ:CRSP) – Oppenheimer issued their Q2 2020 earnings per share (EPS) estimates for Crispr Therapeutics in a research report issued on Tuesday, November 12th, according to Zacks Investment Research. Oppenheimer analyst S. Tuerkcan anticipates that the company will post earnings of ($0.95) per share for the quarter. Oppenheimer has a “Outperform” rating and a $80.00 price objective on the stock. Oppenheimer also issued estimates for Crispr Therapeutics’ Q3 2020 earnings at ($1.29) EPS and Q4 2020 earnings at ($1.38) EPS.
A number of other equities analysts also recently weighed in on the stock. Roth Capital lifted their target price on shares of Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Goldman Sachs Group upped their price target on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research report on Tuesday, November 19th. Piper Jaffray Companies reiterated a “buy” rating and set a $104.00 price target on shares of Crispr Therapeutics in a report on Tuesday, November 26th. Chardan Capital reissued a “buy” rating and issued a $72.50 price objective on shares of Crispr Therapeutics in a research note on Monday, November 18th. Finally, Zacks Investment Research lowered Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $69.54.
Crispr Therapeutics stock traded up $1.66 during mid-day trading on Wednesday, hitting $72.37. 892,934 shares of the stock were exchanged, compared to its average volume of 703,877. Crispr Therapeutics has a 12 month low of $22.22 and a 12 month high of $74.00. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm’s fifty day simple moving average is $54.81 and its two-hundred day simple moving average is $47.38. The stock has a market capitalization of $4.00 billion, a price-to-earnings ratio of -21.04 and a beta of 3.30.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $3.35. The company had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Benjamin Edwards Inc. boosted its position in shares of Crispr Therapeutics by 96.4% during the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after buying an additional 268 shares during the last quarter. NEXT Financial Group Inc boosted its holdings in Crispr Therapeutics by 915.0% during the 3rd quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after acquiring an additional 549 shares during the last quarter. US Bancorp DE boosted its holdings in Crispr Therapeutics by 553.7% during the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after acquiring an additional 526 shares during the last quarter. Coastal Investment Advisors Inc. bought a new stake in shares of Crispr Therapeutics in the 3rd quarter worth $26,000. Finally, BSW Wealth Partners bought a new stake in shares of Crispr Therapeutics in the 2nd quarter worth $39,000. Hedge funds and other institutional investors own 49.81% of the company’s stock.
In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now owns 33,618 shares in the company, valued at $2,353,260. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total value of $412,500.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $412,500. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,118 shares of company stock valued at $3,620,760. Insiders own 21.40% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: The role of implied volatility with call option volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.